Fernando Archie, Fowler Sarah, O'Brien Tim
BAUS, The Royal College of Surgeons of England, London, UK.
The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.
BJU Int. 2016 Jun;117(6):874-82. doi: 10.1111/bju.13353. Epub 2015 Nov 18.
To determine the scope and outcomes of nephron-sparing surgery (NSS), i.e. partial nephrectomy, across the UK and in so doing set a realistic benchmark and identify fresh contemporary challenges in NSS.
In 2012 reporting of outcomes of all types of nephrectomy became mandatory in the UK. In all, 148 surgeons in 86 centres prospectively entered data on 6 042 nephrectomies undertaken in 2012. This study is a retrospective analysis of the NSS procedures in the dataset.
A total of 1 044 NSS procedures were recorded and the median (range) surgical volume was 4 (1-39) per consultant and 8 (1-59) per centre. In all, 36 surgeons and 10 centres reported on only one NSS. The indications for NSS were: elective with a tumour of ≤4.5 cm in 59%, elective with a tumour of >4.5 cm in 10%, relative in 7%, imperative in 12%, Von Hippel-Lindau in 1%, and unknown in 11%. The median (range) tumour size was 3.4 (0.8-30) cm. The technique used was minimally invasive surgery in 42%, open in 58%, with conversions in 4%. The histology results were: malignant in 80%, benign in 18%, and unknown in 2%. In patients aged <40 years 36% (36/101) had benign histology vs 17% (151/874) of those aged ≥40 years (P < 0.01). In patients with tumours of <2.5 cm 29% (69/238) had benign histology vs 14% (57/410) with tumours of 2.5-4 cm vs 8% (16/194) with tumours of ≥4 cm (P = 0.02). In patients aged <40 years with of tumours of <2.5 cm 44% (15/34) were benign. The 30-day mortality was 0.1% (1/1 044). There were major complications (Clavien-Dindo grade of ≥IIIa) in 5% (53/1 044). There was an increased risk of complications after extended elective NSS of 19% (19/101) vs elective at 12% (76/621) (relative risk [RR] 1.54; P < 0.01). Margins were recorded in 68% (709/1 044) of the patients, with positive margins identified in 7% (51/709). Positive surgical margins after NSS for pathological T3 (pT3) tumours were found in 47.8% (11/23) vs 6.1% (32/523) for pT1a, tumours (RR 5.61; P < 0.01). In all, 14% (894/6 042) of the patients underwent surgery for T1a tumours: 55% (488/894) by NSS, 42% (377/894) by radical nephrectomy (RN), and in 3% (29/894) the procedure used was unknown. Major complications after occurred in 4.9% (24/488) of NSS vs 1.3% (5/377) of RN (P < 0.01). Limitations included poor reporting of renal function data and no data on tumour complexity.
In its first year, mandatory national reporting has provided several challenging contemporary insights into NSS.
确定英国肾部分切除术(即保留肾单位手术,NSS)的范围及结果,以此设定一个现实的基准,并识别NSS领域新出现的当代挑战。
2012年起,英国规定必须报告所有类型肾切除术的结果。86个中心的148名外科医生前瞻性地录入了2012年所做6042例肾切除术的数据。本研究是对数据集中NSS手术的回顾性分析。
共记录了1044例NSS手术,每位顾问医生的手术量中位数(范围)为4例(1 - 39例),每个中心为8例(1 - 59例)。共有36名外科医生和10个中心仅报告了1例NSS手术。NSS的适应证为:肿瘤≤4.5 cm的择期手术占59%,肿瘤>4.5 cm的择期手术占10%,相对适应证占7%,绝对适应证占12%,VHL综合征占1%,不明占11%。肿瘤大小中位数(范围)为3.4 cm(0.8 - 30 cm)。手术技术采用微创手术的占42%,开放手术占58%,中转手术占4%。组织学结果为:恶性占80%,良性占18%,不明占2%。年龄<40岁的患者中36%(36/101)组织学为良性,而年龄≥40岁的患者中这一比例为17%(151/874)(P < 0.01)。肿瘤<2.5 cm的患者中29%(69/238)组织学为良性,肿瘤2.5 - 4 cm的患者中这一比例为14%(57/410),肿瘤≥4 cm的患者中为8%(16/194)(P = 0.02)。年龄<40岁且肿瘤<2.5 cm的患者中44%(15/34)为良性。30天死亡率为0.1%(1/1044)。严重并发症(Clavien - Dindo分级≥IIIa级)发生率为5%(53/1044)。延长择期NSS术后并发症风险增加至19%(19/101),而择期手术为12%(76/621)(相对风险[RR] 1.54;P < 0.01)。68%(709/1044)的患者记录了切缘情况,其中切缘阳性的占7%(51/709)。pT3病理肿瘤NSS术后切缘阳性率为47.8%(11/23),而pT1a肿瘤为6.1%(32/523)(RR 5.61;P < 0.01)。共有14%(894/6042)的患者因T1a肿瘤接受手术:55%(488/894)采用NSS,42%(377/894)采用根治性肾切除术(RN),3%(29/894)手术方式不明。NSS术后严重并发症发生率为4.9%(24/488),而RN为1.3%(5/377)(P < 0.01)。局限性包括肾功能数据报告不佳以及缺乏肿瘤复杂性的数据。
在第一年,全国性强制报告为NSS提供了一些具有挑战性的当代见解。